Landmark PRIME Study Shows PreTRM® Test Significantly Reduces Preterm Births and Neonatal Complications
SERA has more than doubled off its 52-week low of $1.37.
Summary
Sera Prognostics reported landmark clinical trial results for its PreTRM® blood test, showing significant reductions in preterm births and improved newborn health outcomes.
Key Events · Product Development and Regulatory · SERA
-
Landmark PRIME Study Results Published
Sera Prognostics announced the publication of positive results from its PRIME study in the Pregnancy Journal, demonstrating the effectiveness of its PreTRM® blood test.
-
Significant Reduction in Preterm Births
The study showed a 56% reduction in babies born before 32 weeks and a 32% reduction before 35 weeks when using the PreTRM® test with targeted interventions.
-
Improved Neonatal Outcomes
Key findings include a 20% reduction in NICU admissions and a 20% decrease in neonatal morbidity, saving one NICU day for every 4.2 patients screened.
-
Jefferies Fireside Chat Scheduled
Company executives will discuss the full PRIME study results during a Jefferies-hosted fireside chat on January 9, 2026.
Analysis · SERA · Industrial Applications And Services
Sera Prognostics announced highly positive results from its landmark PRIME study, published in the Pregnancy Journal. The PreTRM® blood test, combined with targeted interventions, demonstrated a substantial reduction in early preterm births and improved neonatal outcomes. These findings significantly strengthen the clinical evidence for the PreTRM® test-and-treat strategy, potentially expanding its market adoption and value proposition. The upcoming fireside chat with Jefferies will provide further details and insights into these transformative results, which could materially impact the company's commercial trajectory and address a critical unmet medical need.
At the time of this filing, SERA was trading at $2.96 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $114.2M. The 52-week trading range was $1.37 to $8.73. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.